What to do after failure of BCG?

Ashish M. Kamat, MD, MBBS, FACS

Professor of Urologic Oncology
Wayne B. Duddlesten Professor of Cancer Research
President, International Bladder Cancer Group
Associate Cancer Center Director, RFHNH



Why is this important?



~ 1.2 Million Doses of BCG used globally for Bladder Cancer

How common is BCG failure?






Figure 3. RFS according to randomization arm (p = 0.001)


Hemdan et al. J Urol 2014; 191: 1244


Definition of BCG Failure


- Must include clear definition of <u>ADEQUATE</u> prior BCG therapy
- BCG Induction (6 weeks) plus at least one course of Maintenance BCG (3 weeks)
- Persistent disease at/after 6 month time point after initiation of therapy
 - Exception Ta/Tis -> T1 at 3 mos











64% of 'failures' salvaged with 3 weeks of BCG

BCG unresponsive NMIBC

Persistent high grade disease at 6 months cysto afte BCG-Unresponsive
 Nonmuscle Invasive Bladder
 Cancer: Developing Drugs and Biologics for Treatment t 3 mos

Guidance for Industry

Recurrence of HG disease while on maintenance therapy

CYS

Kamat et al, JCO, 2016; Lerner et al, Bladder Cancer, 2016

Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

Ashish M. Kamat, Richard J. Sylvester, Andreas Böhle, Joan Palou, Donald L. Lamm, Maurizio Brausi, Mark Soloway, Raj Persad, Roger Buckley, Marc Colombel, and J. Alfred Witjes

BCG Unresponsive CIS

Initial complete response (CR) of 50% at 6 months; durable response rate of at least 30% at 12 months and 25% at 18 months


BCG Unresponsive papillary disease


Recurrence free rate of 30% at 12 months and 25% at 18 months




BCG Unresponsive Non-muscle Invasive Bladder Cancer: Definition, Treatment Options and Management Recommendations from the IBCG

Ashish Kamat¹, Marc Colombel², Debasish Sundi¹, Donald Lamm³, Andreas Boehle⁴, Maurizio Brausi⁵, Roger Buckley⁶, Raj Persad⁷, Joan Palou⁸, Mark Soloway⁹, J. Alfred Witjes¹⁰








Options for Intravesical Therapy after BCG




Making Cancer History*

What About Repeat BCG?



Catalona WJ, et al J Urol

BCG plus interferon-α (INF-α)



Gallagher BL et al, Urology, 20008

Valrubicin

 FDA approved in 1998 for BCG-refractory CIS in those who are not candidates for cystectomy

CR at 6 months in 18% of patients

2-year DFS only 4%



Steinberg et al, J Urol, 1998; Dinney et al, Urol Onc, 2013.

SWOG S0353 Phase II Gemcitabine






- Minimum of 2 courses of BCG
- Tis, T1, Ta high-grade, or Ta low-grade with >2 lesions
- 2gm Gem weekly x6, monthly to 12 months

Skinner, J Urol, 2013


Sequential Doublet Chemotherapy with Gemcitabine – Mitomycin for HG BCG Refractory



Independent validation 37% NED at 22 months; n = 27 (Cockerill, BJUI Lightfoot, O'Donnell, Urol Oncol 2015)

Lightfoot, O'Donnell, Urol Oncol 2014

Sequential Gemcitabine-Docetaxel



64% CIS; 91% HG 38% BCG Fx1; 53% BCG

Steinberg, O'Donnell, Bladder Ca, 2015

Gemcitabine Docetaxel Regimen

- Gemcitabine: 1 g in 50 ml of sterile water via catheter, plugged, and retained for 90 minutes.
- Docetaxel: drain bladder, then 37.5 mg of docetaxel in 50 mL of saline is instilled
- Catheter removed, patients are instructed to not urinate for 2 hrs

1300 mg oral sodium bicarbonate evening prior and morning of treatment to alkalinize their urine.

Prevent some side effects of acidic gemcitabine (pH 2.5); modify for sicker patients with sodium load.

Oral and ansetron prophylactically to natients who report nausea after their first instillation

Hyperthermic MMC post BCG

111 patients with recurrent papillary NMIBC after BCG




Figure 3. Disease-free survival. A, vs tumor recurrence history. Blue curve indicates highly recurrent. Green curve indicates other. B, vs EAU risk group. Blue curve indicates high risk. Green curve indicates intermediate risk. Vertical lines indicate censored.


- DFS estimates:
 - 85% and 56% after 1 and 2 years, respectively.
 - 38% were BCG refractory and 17% relapsed within 12 mos of BCG

Nativ O, Witjes at al J Urol.

Mycobacterium cell wall-DNA complex


- Reanalysis of subset that was BCG Unresponsive
- 1 yr DFS: 35% in BCG unresponsive vs. 25% overall
 - Papillary: 61% and 51% at 1 & 2 yrs, respectively

K-M Curves of DFS - BCG Unresponsive Subjects vs. Rest of the Subjects



Censored observations are indicated by dots

Instiladrin rAd-IFN-CS-003 – Phase 3 (n = 135)



Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study

Neal D. Shore, Stephen A. Boorjian, Daniel J. Canter, Kenneth Ogan, Lawrence I. Karsh, Tracy M. Downs, Leonard G. Gomella, Ashish M. Kamat, Yair Lotan, Robert S. Svatek, Trinity J. Bivalacqua, Robert L. Grubb III, Tracey L. Krupski, Seth P. Lerner, Michael E. Woods, Brant A. Inman, Matthew I. Milowsky, Alan Boyd, F. Peter Treasure, Gillian Gregory, David G. Sawutz, Seppo Yla-Herttuala, Nigel R. Parker, and Colin P.N. Dinney


- At 12 months: 40 patients (35%) free of high grade disease
 - No grade 4/5 AE
 - No treatment discontinuation due to AE

Pembrolizumab in Patients With Bacillus Calmette Guérin (BCG)—Unresponsive, High-Risk Non—Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 Study

<u>Ashish M. Kamat,</u> Ronald de Wit,² Joaquim Bellmunt,³ Toni K. Choueiri,⁴ Kijoeng Nam,⁵ Maria De Santis,⁶ Robert Dreicer,⁷ Noah M. Hahn,⁸ Rodolfo Perini,⁵ Arlene Siefker-Radtke,² Guru Sonpavde,⁹ J. Alfred Witjes,¹⁰ Stephen Keefe,⁵ Dean Bajorin¹¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Erasmus MC Cancer Institute, Rotterdam, Netherlands; ³Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ⁴Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA; ⁵Merck & Co., Inc., Kenilworth, NJ, USA; ⁶University of Warwick, Coventry, United Kingdom; ⁷University of Virginia School of Medicine, Charlottesville, VA, USA; ⁸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA; ⁹University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA; ¹⁰Radboud University, Nijmegen, Netherlands; ¹¹Memorial Sloan Kettering Cancer Center, New York, NY, USA

Localized UC Registration Trials



BCG Failure - Summary

- Make sure patient is truly BCG Unresponsive
- Radical Cystectomy treatment of choice
 - recommended by AUA, EAU, IBCG guidelines
- Options for intravesical therapy
 - Combination chemotherapy
 - Hyperthermic chemotherapy
- Enroll in clinical trials!





Ashish M. Kamat, MD, MBBS, FACS

akamat@mdanderson.org

